Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
Over the last 12 months, insiders at Supernus Pharmaceuticals, Inc. have bought $0 and sold $4.35M worth of Supernus Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Supernus Pharmaceuticals, Inc. have bought $379,964 and sold $5.17M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 14,400 shares for transaction amount of $379,964 was made by Khattar Jack A. (President, CEO) on 2019‑08‑23.
2024-03-21 | Sale | Bhatt Padmanabh P. | Sr. VP of IP, CSO | 14,491 0.0266% | $35.31 | $511,677 | -16.66% | |
2024-03-20 | Sale | Bhatt Padmanabh P. | Sr. VP of IP, CSO | 400 0.0007% | $35.31 | $14,124 | -15.85% | |
2024-03-19 | Sale | Bhatt Padmanabh P. | Sr. VP of IP, CSO | 12,364 0.0227% | $35.31 | $436,573 | -16.39% | |
2024-03-13 | Sale | Bhatt Padmanabh P. | Sr. VP of IP, CSO | 62,366 0.1107% | $33.74 | $2.1M | -14.39% | |
2024-03-12 | Sale | Bhatt Padmanabh P. | Sr. VP of IP, CSO | 3,884 0.0071% | $32.99 | $128,133 | -9.79% | |
2024-02-26 | Sale | Bhatt Padmanabh P. | Sr. VP of IP, CSO | 5,000 0.0094% | $30.21 | $151,050 | +1.93% | |
2024-01-10 | Sale | Martin Tami Tillotson | Sr. V.P., Regulatory Affairs | 8,000 0.0146% | $27.91 | $223,280 | +3.96% | |
2023-11-16 | Sale | NEWHALL CHARLES W III | director | 2,500 0.0046% | $28.01 | $70,025 | +1.78% | |
2023-11-15 | Sale | Hudson Frederick M. | director | 9,093 0.0166% | $28.50 | $259,151 | -0.35% | |
2023-11-14 | Sale | Mottola Frank | SVP, Quality, GMP, Ops, IT | 1,110 0.002% | $28.13 | $31,224 | +0.80% | |
2023-08-30 | Sale | Martin Tami Tillotson | Sr. V.P., Regulatory Affairs | 8,100 0.0149% | $32.00 | $259,200 | -12.20% | |
2023-08-25 | Sale | Martin Tami Tillotson | Sr. V.P., Regulatory Affairs | 5,135 0.0095% | $31.59 | $162,215 | -10.49% | |
2023-03-14 | Sale | Mottola Frank | Sr VP, Quality, GMP Oper. & IT | 4,780 0.0087% | $35.99 | $172,023 | -17.41% | |
2023-02-03 | Sale | Khattar Jack A. | President, CEO | 200 0.0004% | $42.02 | $8,404 | -26.44% | |
2023-02-02 | Sale | Khattar Jack A. | President, CEO | 13,532 0.0249% | $42.05 | $569,088 | -27.12% | |
2023-02-01 | Sale | Khattar Jack A. | President, CEO | 300 0.0006% | $42.01 | $12,602 | -26.24% | |
2023-01-31 | Sale | Khattar Jack A. | President, CEO | 976 0.0018% | $42.01 | $41,002 | -25.14% | |
2023-01-18 | Sale | Khattar Jack A. | President, CEO | 4,936 0.0091% | $40.40 | $199,394 | -21.48% | |
2023-01-17 | Sale | Khattar Jack A. | President, CEO | 25,446 0.0467% | $40.03 | $1.02M | -21.01% | |
2023-01-17 | Sale | Bhatt Padmanabh P. | Sr. VP of IP, CSO | 4,826 0.0088% | $39.92 | $192,638 | -21.01% |
NEWHALL CHARLES W III | director | 117089 0.2143% | $26.72 | 1 | 1 | +29.48% |
Martin Tami Tillotson | Sr. V.P., Regulatory Affairs | 85664 0.1568% | $26.72 | 1 | 7 | +29.48% |
Hudson Frederick M. | director | 33231 0.0608% | $26.72 | 1 | 2 | +29.48% |
Mottola Frank | SVP, Quality, GMP, Ops, IT | 5681 0.0104% | $26.72 | 0 | 2 | |
Bhatt Padmanabh P. | Sr. VP of IP, CSO | 8570 0.003% | $26.72 | 0 | 33 | |
NEW ENTERPRISE ASSOCIATES 11 LP | 10 percent owner | 10641250 19.4778% | $26.72 | 1 | 0 | +29.48% |
Abingworth Management LTD | 10 percent owner | 3600000 6.5894% | $26.72 | 1 | 0 | +29.48% |
SHEFFERY MICHAEL B | director | 2402600 4.3977% | $26.72 | 1 | 0 | +29.48% |
ORBIMED ADVISORS LLC | 10 percent owner | 817000 1.4954% | $26.72 | 1 | 4 | +29.48% |
Khattar Jack A. | President, CEO | 804272 1.4721% | $26.72 | 3 | 18 | +14.22% |
Bryan Jones W. | VP of Business Development | 67980 0.1244% | $26.72 | 0 | 2 | |
PATRICK GREGORY S | Sr. VP Chief Financial Officer | 44463 0.0814% | $26.72 | 2 | 14 | +14.05% |
BIGHAM MICHAEL | director | 25000 0.0458% | $26.72 | 2 | 0 | +20.85% |
Nuerge William A. | director | 23750 0.0435% | $26.72 | 1 | 0 | +29.48% |
SIEBERT JOHN M | director | 15188 0.0278% | $26.72 | 3 | 0 | +13.12% |
Vaughn Victor | Sr. VP of Sales & Marketing | 9344 0.0171% | $26.72 | 0 | 7 | |
Schwabe Stefan K.F. | Executive Vice President & CMO | 2772 0.0051% | $26.72 | 0 | 8 | |
BARRIS PETER J | 10 percent owner | 0 0% | $26.72 | 0 | 2 | |
BASKETT FOREST | 10 percent owner | 0 0% | $26.72 | 0 | 2 | |
BARRETT M JAMES | director | 0 0% | $26.72 | 1 | 10 | +29.48% |
SANDELL SCOTT D | 10 percent owner | 0 0% | $26.72 | 0 | 2 |
BlackRock | $353.46M | 18.85 | 10.36M | -0.2% | -$696,321.54 | 0.01 | |
The Vanguard Group | $211.71M | 11.29 | 6.21M | -0.13% | -$270,048.87 | <0.01 | |
Armistice Capital Llc | $121.84M | 6.5 | 3.57M | -23.18% | -$36.77M | 1.46 | |
Macquarie Group | $91.04M | 4.86 | 2.67M | -2.51% | -$2.34M | 0.07 | |
Dimensional Fund Advisors | $87.22M | 4.65 | 2.56M | +4.09% | +$3.43M | 0.02 | |
State Street | $69.54M | 3.71 | 2.04M | -1.15% | -$807,724.80 | <0.01 | |
Polar Capital | $66.19M | 3.53 | 1.94M | +0.06% | +$39,055.95 | 0.37 | |
Stephens Investment Management Group LLC | $64.87M | 3.46 | 1.9M | -0.16% | -$105,331.68 | 0.86 | |
Loomis, Sayles & Company | $54.49M | 2.91 | 1.6M | -2.39% | -$1.33M | 0.08 | |
GW&K Investment Management | $45.69M | 2.44 | 1.34M | +1.66% | +$747,548.76 | 0.4 | |
Renaissance Technologies | $45.48M | 2.42 | 1.33M | -3.28% | -$1.54M | 0.07 | |
Geode Capital Management | $44.59M | 2.38 | 1.31M | +4.96% | +$2.11M | <0.01 | |
Woodline Partners LP | $44.05M | 2.35 | 1.29M | New | +$44.05M | 0.42 | |
Aristotle Capital Boston LLC | $38.88M | 2.07 | 1.14M | -1.72% | -$681,585.93 | 1.2 | |
Congress Asset Management Co Ma | $35.21M | 1.88 | 1.03M | +12.09% | +$3.8M | 0.25 | |
Ashford Capital Management Inc | $26.04M | 1.39 | 763,465 | -7.63% | -$2.15M | 3.53 | |
Morgan Stanley | $22.18M | 1.18 | 650,226 | -10.11% | -$2.49M | <0.01 | |
Victory Capital Management Inc | $22.1M | 1.18 | 647,838 | -6.17% | -$1.45M | 0.02 | |
Northern Trust | $21.12M | 1.13 | 619,213 | -4.51% | -$997,137.66 | <0.01 | |
Invesco | $20.59M | 1.1 | 603,774 | +13.93% | +$2.52M | <0.01 | |
Charles Schwab | $20.22M | 1.08 | 592,646 | +6.6% | +$1.25M | 0.01 | |
Ameriprise Financial | $19.31M | 1.03 | 566,270 | +1.17% | +$223,967.78 | 0.01 | |
Rice Hall James & Associates, LLC | $17.63M | 0.94 | 516,773 | -2.49% | -$449,535.69 | 1.07 | |
T. Rowe Price | $15.1M | 0.81 | 442,757 | -0.57% | -$87,290.72 | <0.01 | |
BNY Mellon | $14.43M | 0.77 | 422,960 | -5.03% | -$764,473.61 | <0.01 | |
Bank of America | $12.3M | 0.66 | 360,599 | -1.12% | -$139,134.69 | <0.01 | |
Schroder Investment Management Group | $12.2M | 0.65 | 357,681 | -34% | -$6.29M | 0.01 | |
Tributary Capital Management | $11.76M | 0.63 | 344,838 | -0.41% | -$48,538.53 | 0.97 | |
SEI Investments Company | $11.28M | 0.6 | 330,580 | +24.36% | +$2.21M | 0.02 | |
Mutual Of America Capital Management Llc | $10.95M | 0.58 | 320,920 | -4.97% | -$572,604.56 | 0.12 | |
Goldman Sachs | $10.74M | 0.57 | 314,894 | +31.68% | +$2.58M | <0.01 | |
Scout Investments | $8.9M | 0.48 | 265,525 | -5.98% | -$565,650.00 | 0.22 | |
Nuveen | $7.74M | 0.41 | 227,032 | +73.66% | +$3.28M | <0.01 | |
PEREGRINE CAPITAL MANAGEMENT INC | $6.92M | 0.37 | 202,993 | New | +$6.92M | 0.2 | |
Epoch Investment Partners Inc | $6.9M | 0.37 | 202,267 | -41.6% | -$4.91M | 0.03 | |
JPMorgan Chase | $6.72M | 0.36 | 197,114 | +26.56% | +$1.41M | <0.01 | |
HSBC | $6.38M | 0.34 | 187,404 | +1,719.28% | +$6.03M | 0.01 | |
Congress Wealth Management Llc De | $6.06M | 0.32 | 177,801 | +37.78% | +$1.66M | 0.11 | |
S&T Bank | $5.99M | 0.32 | 175,564 | -7.28% | -$470,406.78 | 1.15 | |
RhumbLine Advisers | $5.95M | 0.32 | 174,461 | -1.83% | -$111,198.10 | 0.01 | |
Dz Bank Ag Deutsche Zentral Genossenschafts Bank Frankfurt Am Main | $5.92M | 0.32 | 173,618 | New | +$5.92M | 0.01 | |
Third Avenue Management | $5.45M | 0.29 | 159,717 | 0% | +$0 | 0.87 | |
Legal & General | $5.18M | 0.28 | 151,903 | -1.84% | -$97,213.48 | <0.01 | |
Two Sigma Advisers LP | $4.89M | 0.26 | 143,300 | -36.9% | -$2.86M | 0.01 | |
D. E. Shaw & Co. | $4.45M | 0.24 | 130,366 | +0.94% | +$41,375.43 | 0.01 | |
Point72 Asset Management | $4.36M | 0.23 | 127,821 | New | +$4.36M | 0.01 | |
Phocas Financial Corp | $3.52M | 0.22 | 121,559 | 0% | +$0 | 0.37 | |
Public Sector Pension Investment Board | $3.82M | 0.2 | 111,982 | -1.23% | -$47,412.90 | 0.03 | |
Swiss National Bank | $3.67M | 0.2 | 107,600 | 0% | +$0 | <0.01 | |
American Century Investments | $3.65M | 0.2 | 106,930 | +47.3% | +$1.17M | <0.01 |